JP2012521353A5 - - Google Patents

Download PDF

Info

Publication number
JP2012521353A5
JP2012521353A5 JP2012500985A JP2012500985A JP2012521353A5 JP 2012521353 A5 JP2012521353 A5 JP 2012521353A5 JP 2012500985 A JP2012500985 A JP 2012500985A JP 2012500985 A JP2012500985 A JP 2012500985A JP 2012521353 A5 JP2012521353 A5 JP 2012521353A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
group
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012500985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521353A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/027915 external-priority patent/WO2010108067A1/en
Publication of JP2012521353A publication Critical patent/JP2012521353A/ja
Publication of JP2012521353A5 publication Critical patent/JP2012521353A5/ja
Withdrawn legal-status Critical Current

Links

JP2012500985A 2009-03-20 2010-03-19 アルファ−(n−ベンゼンスルホンアミド)シクロアルキル誘導体 Withdrawn JP2012521353A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16185209P 2009-03-20 2009-03-20
US61/161,852 2009-03-20
PCT/US2010/027915 WO2010108067A1 (en) 2009-03-20 2010-03-19 Alpha-(n-benzenesulfonamido)cycloalkyl derivatives

Publications (2)

Publication Number Publication Date
JP2012521353A JP2012521353A (ja) 2012-09-13
JP2012521353A5 true JP2012521353A5 (enExample) 2013-04-11

Family

ID=42235839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012500985A Withdrawn JP2012521353A (ja) 2009-03-20 2010-03-19 アルファ−(n−ベンゼンスルホンアミド)シクロアルキル誘導体

Country Status (5)

Country Link
US (1) US7977362B2 (enExample)
EP (1) EP2408756B1 (enExample)
JP (1) JP2012521353A (enExample)
CN (1) CN102428074A (enExample)
WO (1) WO2010108067A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471099C (en) 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
EP2471363A1 (de) 2010-12-30 2012-07-04 Bayer CropScience AG Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen
WO2013052700A1 (en) * 2011-10-04 2013-04-11 The Brigham And Women's Hospital, Inc. Novel sulfonamides
WO2018108627A1 (de) 2016-12-12 2018-06-21 Bayer Cropscience Aktiengesellschaft Verwendung substituierter indolinylmethylsulfonamide oder deren salze zur steigerung der stresstoleranz in pflanzen
WO2019025153A1 (de) 2017-07-31 2019-02-07 Bayer Cropscience Aktiengesellschaft Verwendung von substituierten n-sulfonyl-n'-aryldiaminoalkanen und n-sulfonyl-n'-heteroaryldiaminoalkanen oder deren salzen zur steigerung der stresstoleranz in pflanzen

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5583221A (en) 1994-05-04 1996-12-10 Eli Lilly And Company Substituted fused and bridged bicyclic compounds as therapeutic agents
SK282833B6 (sk) 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
JP2000515153A (ja) 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するTNF―α産生抑制剤
AU766192B2 (en) 1999-01-27 2003-10-09 Wyeth Holdings Corporation Acetylenic sulfonamide thiol tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
CA2471099C (en) * 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
KR20060002908A (ko) 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
CA2544350A1 (en) * 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US7163942B2 (en) * 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
EP1768960A1 (en) * 2004-07-13 2007-04-04 F.Hoffmann-La Roche Ag Sulfonamide derivatives
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
EP1984321A1 (en) 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
AR059517A1 (es) 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
WO2009137657A1 (en) 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
CN102438622A (zh) 2009-03-19 2012-05-02 百时美施贵宝公司 作为β淀粉样肽产生抑制剂的新颖α-(N-磺酰氨基)乙酰胺化合物
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Similar Documents

Publication Publication Date Title
JP2012521353A5 (enExample)
JP2016503793A5 (enExample)
JP2015505296A5 (enExample)
JP2013513621A5 (enExample)
JP2016040288A5 (enExample)
JP2013537203A5 (enExample)
JP2010155827A5 (enExample)
JP2016503797A5 (enExample)
JP2011518833A5 (enExample)
JP2012092103A5 (enExample)
JP2015520140A5 (enExample)
JP2013542261A5 (enExample)
JP2014506907A5 (enExample)
JP2008501000A5 (enExample)
JP2013540713A5 (enExample)
JP2014526533A5 (enExample)
JP2018537535A5 (enExample)
JP2015500843A5 (enExample)
JP2014507455A5 (enExample)
JP2016518437A5 (enExample)
JP2015512931A5 (enExample)
JP2013507423A5 (enExample)
JP2013531008A5 (enExample)
JP2017501236A5 (enExample)
JP2017517538A5 (enExample)